REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the fiscal year ended
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Securities registered or to be registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
|
|
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
|
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
|
☒
|
☐ Accelerated filer
|
☐ Non-accelerated filer
|
|
☒
|
International Financial Reporting Standards as issued by the International Accounting Standards Board ☐
|
Other ☐
|
• |
Other foundries may bid against us to acquire potential targets. This competition may result in decreased availability of, or increased
prices for, suitable acquisition candidates; |
• |
We may not be able to obtain the necessary regulatory or other approvals, and as a result, or for other reasons, we may fail to consummate
certain acquisitions; |
• |
Potential acquisitions and execution of an expansion plan may require the dedication of substantial management effort, time and resources
which may divert management from our existing business operations or other strategic opportunities; |
• |
We may not be able to retain experienced management and skilled employees from the businesses we acquire and, if we cannot retain
such personnel, we may not be able to attract new skilled employees and experienced management to replace them; |
• |
We may purchase a company with excessive unknown contingent liabilities and/or a cost structure that is not as beneficial as anticipated
from the preliminary evaluation or that includes high cost that may result in losses incurred by us if we do not succeed in maintaining
high utilization levels to cover the cost; |
• |
We may not be able to obtain sufficient financing which could limit our ability to engage in certain acquisitions and strategic engagements;
and |
• |
The amount or terms of financing actually required before and after acquisitions considering our current liquidity and cash position
may vary from our expectations, resulting in a need for more funding that may not be available to us in order to finance acquisitions,
the operations of the target acquired and/or the acquisition of additional equipment that may be required to increase and/or adjust the
target’s operations to address our customer demand and specific technology flows, which may adversely affect our liquidity and balance
sheet position. |
• |
JPY and NIS fluctuations against the USD – see the risk factor below entitled: “Our
exposure to currency exchange and interest rate fluctuations may impact our costs and financial results”; |
• |
the burden and cost of compliance with foreign government regulation, as well as compliance with a variety of foreign laws, and the
imposition of regulatory requirements, tariffs, import and export restrictions and other trade barriers and restrictions, including the
timing and availability of export licenses and permits; |
• |
general geopolitical risks, such as political and economic instability, international terrorism, potential hostilities and changes
in diplomatic and trade relationships; |
• |
adverse foreign and international tax rules and regulations, such as withholding taxes deducted from amounts due to us
and not refunded to us by the tax authorities since we are not entitled to foreign tax credit in Israel; |
• |
weak protection of our intellectual property rights in certain foreign countries; |
• |
delays in wafer shipments due to local customs restrictions; |
• |
laws and business practices favoring local companies; |
• |
difficulties in collecting accounts receivable; and |
• |
difficulties and costs of staffing and managing foreign operations. |
• |
limiting our ability to fulfill our debt obligations and other liabilities; |
• |
requiring the use of a portion of our cash to service our indebtedness rather than investing our cash to fund our strategic growth
opportunities and plans, working capital and capital expenditures; |
• |
increasing our vulnerability to adverse economic and industry conditions; |
• |
limiting our ability to obtain additional financing; |
• |
limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; |
• |
placing us at a competitive disadvantage with respect to less leveraged competitors and competitors that have better access to capital
resources; |
• |
volatility in our non-cash financing expenses due to increases in the fair value of our debt obligations; |
• |
fluctuations of the payable amounts in USD of the JPY-denominated loans and capital lease agreements or other expenses denominated
in JPY; and |
• |
potential enforcement by the lenders of their liens against our respective assets, as applicable, if an event of default occurs.
|
• |
fluctuations in the level of revenues from our operating activities; |
• |
fluctuations in the collection of receivables; |
• |
timing and size of payables; |
• |
the timing and size of capital expenditures; |
• |
the net impact of JPY/ USD fluctuations on our JPY income and JPY cost; |
• |
the impact of capital market conditions on our marketable securities; |
• |
the repayment schedules of our debt obligations; |
• |
our ability to fulfill our obligations and meet performance milestones under our agreements; |
• |
fluctuations in the USD to NIS exchange rate; and |
• |
the inflation rates in Israel, Japan and the United States. |
• |
changes in the volume and mix of profits earned across jurisdictions with varying tax rates; |
• |
changes in our business or legal entity operating model; |
• |
the resolution of issues, including transfer pricing implementation, arising from tax audits; |
• |
changes in the valuation of our deferred tax assets and liabilities, and in deferred tax valuation allowances; |
• |
increases in expenses not deductible for tax purposes, or deductible for extended period; |
• |
changes in available tax credits, including, research and development credits; |
• |
changes in income tax codes or foreign tax laws or their interpretation; |
• |
changes, reduction, cancellation or discontinuation of the tax benefits provided to a “Preferred Enterprise” and its
applicability to Tower’s income under the Israeli Law for the Encouragement of Capital Investments, 5719-1959 (the “Investment
Law”) (see “Item 10. Additional Information—E. Taxation—Israeli Taxation—Law for the Encouragement of Capital
Investments, 5719-1959”); and |
• |
the global implementation of a minimum corporate tax rate under Pillar Two of the Organization for Economic
Cooperation and Development (“OECD”) Base Erosion and Profit Shifting (“BEPS”) initiative, which may cause an
increase of the income tax rate that applies to Tower’s taxable income from 7.5% to a higher rate for periods commencing not before
2026 (see “Item 10. Additional Information—E. Taxation—Israeli Taxation—Law for the Encouragement of Capital Investments,
5719-1959”). |
• |
attempting to negotiate cross-license agreements, which we might not succeed in negotiating or consummating; |
• |
acquiring licenses to the allegedly infringed patents, which may not be available on commercially reasonable terms, if at all;
|
• |
discontinuing use of certain process technologies, architectures, or designs, which could cause us to halt a portion of our operations
if we are unable to design around the allegedly infringed patents; |
• |
litigating the matter in court, which may result in substantial legal fees and paying substantial monetary damages in the event we
lose; or |
• |
developing non-infringing technologies, which may be costly or may not be feasible. |
• |
technical evaluation; |
• |
wafer design to our specifications, including integration of third party intellectual property; |
• |
photomask–- design and order third-party photomask ; |
• |
silicon prototyping; |
• |
assembly and test; |
• |
validation and qualification; and |
• |
production. |
Year ended December 31, | ||||||||||||
2023 |
2022 |
2021 |
||||||||||
United States |
46 |
% |
49 |
% |
41 |
% | ||||||
Japan |
17 |
% |
16 |
% |
22 |
% | ||||||
Asia, excluding Japan |
27 |
% |
26 |
% |
30 |
% | ||||||
Europe |
10 |
% |
9 |
% |
7 |
% | ||||||
Total |
100 |
% |
100 |
% |
100 |
% |
• |
technology offering and future roadmap; |
• |
wafer performance; |
• |
system level technical expertise; |
• |
research and development capabilities; |
• |
access to intellectual property; |
• |
customer technical support; |
• |
design services; |
• |
product development kits (PDKs); |
• |
operational performance; |
• |
quality systems; |
• |
wafer quality; |
• |
operational yields; |
• |
customer support and service; |
• |
pricing; |
• |
management expertise; |
• |
strategic customer relationships; |
• |
capacity availability; and |
• |
stability and reliability of supply. |
Year ended December 31, |
||||||||
2023 |
2022 |
|||||||
Statement of Operations Data: |
||||||||
Revenues |
100 |
% |
100 |
% | ||||
Cost of revenues |
75.2 |
72.2 |
||||||
Gross Profit |
24.8 |
27.8 |
||||||
Research and development expense |
5.6 |
5.0 |
||||||
Marketing, general and administrative expense |
5.1 |
4.8 |
||||||
Restructuring gain from sale of machinery and equipment, net |
(3.7 |
) |
(1.2 |
) | ||||
Restructuring expense |
1.3 |
0.6 |
||||||
Merger-contract termination fee, net |
(22.0 |
) |
-- |
|||||
Operating profit |
38.5 |
18.6 |
||||||
Financing income (expense), net |
2.1 |
(0.8 |
) | |||||
Other income (expense), net |
0.5 |
(0.4 |
) | |||||
Profit before income tax |
41.1 |
17.4 |
||||||
Income tax expense, net |
(4.6 |
) |
(1.5 |
) | ||||
Net profit |
36.5 |
15.9 |
||||||
Net income attributable to non-controlling interest |
(0.1 |
) |
(0.1 |
) | ||||
Net profit attributable to the Company |
36.4 |
% |
15.8 |
% |
Officer |
Senior Management Name |
Age |
Title(s) | |||
A |
Russell C. Ellwanger |
69 |
Chief Executive Officer and Director of Tower, and Chairman of the Board of Directors
of its subsidiaries Tower Semiconductor USA, Inc., Tower US Holdings, Inc., Tower Semiconductor NPB Holdings, Inc., Tower Semiconductor
Newport Beach, Inc., Tower Partners Semiconductor Co., Ltd., Tower Semiconductor San Antonio, Inc. and Tower Semiconductor Italy, S.r.l.
| |||
B |
Oren Shirazi |
54 |
Chief Financial Officer, Senior Vice President of Finance | |||
C |
Rafi Mor |
60 |
Chief Operating Officer | |||
D |
Dr. Marco Racanelli |
57 |
President | |||
E |
Dr. Avi Strum |
61 |
Chief Technology Officer | |||
Director’s Name(*) |
Age |
Title | ||||
F |
Amir Elstein |
68 |
Chairman of the Board of Directors | |||
G |
Kalman Kaufman |
78 |
Director | |||
H |
Dana Gross |
56 |
Director | |||
I |
Ilan Flato |
67 |
Director | |||
J |
Yoav Z. Chelouche |
70 |
Director | |||
K |
Iris Avner |
59 |
Director | |||
L |
Michal Vakrat Wolkin |
52 |
Director | |||
M |
Avi Hasson |
53 |
Director |
• |
the education, skills, expertise and achievements of the relevant office holder; |
• |
the role and responsibilities of the office holder, and prior compensation arrangements with the office holder; |
• |
the ratio of the cost of the terms of employment of an office holder to the cost of compensation of the other employees of the company
(including any employees employed through manpower companies), specifically to the cost of the average and median salaries of such employees
and the impact of the disparities between them upon work relationships in the company; |
• |
with respect to variable compensation, the possibility of reducing variable compensation at the discretion of the board of directors,
and the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and |
• |
with respect to severance compensation, the period of employment or service of the office holder, the terms of his or her compensation
during such period, the company’s performance during such period, the person’s contribution towards the company’s achievement
of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. |
• |
The company does not have a controlling shareholder; and |
• |
The company complies with the requirements of the securities laws and stock exchange regulations in the foreign jurisdiction where
its shares are listed relating to the appointment of independent directors and composition of the audit and compensation committees as
applicable to companies that are incorporated under the laws of such foreign jurisdiction. |
• |
retaining and terminating our independent auditors, subject to the ratification of the board of directors, and in the case of retention,
to that of the shareholders, as applicable in accordance with the Companies Law; |
• |
pre-approving of audit and non-audit services and related fees and terms, to be provided by the independent auditors; |
• |
overseeing the accounting and financial reporting processes of our company and audits of our financial statements and the effectiveness
of our internal control over financial reporting; |
• |
reviewing with management and our independent auditor our annual and quarterly financial statements prior to publication or filing
(or submission, as the case may be); |
• |
recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor’s engagement
fees and terms, in accordance with the Companies Law as well as approving the yearly or multi-year plan proposed by the internal auditor,
and review the results and findings of internal audits; |
• |
overseeing the Company’s risk assessment and reviewing regulatory compliance; |
• |
determining whether to approve certain related party transactions (including transactions in which an office holder has a personal
interest) and whether any such transaction is extraordinary or material under Companies Law; |
• |
determining whether a competitive process must be implemented for the approval of certain transaction(s) with controlling shareholder(s)
or its relative or in which a controlling shareholder has a personal interest (whether or not the transaction is an extraordinary transaction),
under the supervision of the audit committee or other party determined by the audit committee and in accordance with standards to be determined
by the audit committee, or whether a different process determined by the audit committee should be implemented for the approval of such
transaction(s); |
• |
determining the process for the approval of certain transactions with controlling shareholders or in which a controlling shareholder
has a personal interest that the audit committee has determined are not extraordinary transactions but are not immaterial transactions;
and |
• |
responsible for the handling of employees’ complaints as to the management of our business and the protection to be provided
to such employees. |
• |
recommending to the Board of Directors for its approval (i) a compensation policy for officers and directors, (ii) once every three
years, extension of the compensation policy (either a new compensation policy or the continuation of an existing compensation policy must
in any case occur every three years); and (iii) periodic updates to the compensation policy. In addition, the compensation committee is
required to assess the implementation of the compensation policy; |
• |
approving transactions relating to the terms of office and employment of office holders (within the meaning of the Companies Law),
which require the approval of the compensation committee pursuant to the Companies Law; and |
• |
reviewing and approving equity grants to non-executive employees under our equity-based incentive plans. |
• |
overseeing and assisting our board of directors in reviewing and recommending nominees for election as directors; |
• |
assessing the performance of the members of our board of directors; |
• |
reviewing and recommending to our board of directors the structure and members of committees of the board; |
• |
assisting our board of directors in carrying out its responsibilities related to chief executive officer succession planning;
|
• |
reviewing and overseeing our corporate governance practices and communication plans for shareholder meetings and to promote effective
communication for shareholder meetings; and |
• |
overseeing our commitment to ESG matters and advising our board of directors on such matters. |
As of December 31, |
||||||||||||
2023 |
2022 |
2021 |
||||||||||
Process and product engineering, R&D and design |
887 |
1,067 |
1,045 |
|||||||||
Operations |
3,491 |
3,858 |
4,168 |
|||||||||
Operations support |
544 |
410 |
386 |
|||||||||
Sales and marketing, finance & administration |
293 |
278 |
288 |
|||||||||
Total |
5,215 |
5,613 |
5,887 |
Ordinary Shares Beneficially Owned |
||||||||
Name of Beneficial Owner |
Number |
Percent (1) |
||||||
Migdal Insurance & Financial Holdings Ltd (2) |
8,402,025 |
7.57 |
% | |||||
Harel Insurance Investments & Financial Services (3) |
8,216,838 |
7.40 |
% | |||||
Senvest Management, LLC (4) |
8,033,256 |
7.24 |
% | |||||
Clal Insurance Enterprises Holdings Ltd. (5) |
5,617,259 |
5.06 |
% |
(1) |
In accordance with the rules of the SEC, assumes (i) the holder’s beneficial ownership of outstanding ordinary shares and all
ordinary shares that the holder has a right to purchase within 60 days of March 31, 2024; and (ii) no other exercisable or convertible
securities held by other holders has been exercised or converted into ordinary shares. |
(2) |
Based solely upon and qualified in its entirety with reference to, a notice provided to the Company by Migdal Insurance & Financial Holdings Ltd.
as of March 31, 2024. Based solely upon, and qualified in its entirety with reference to, information provided to the Company by Migdal
Insurance & Financial Holdings Ltd. and public filings, we believe the percentage of our ordinary shares beneficially owned by Migdal
Insurance & Financial Holdings Ltd. during the past three years has ranged between 3.8% and 7.6%, however, there is no assurance this
shareholder did not own fewer shares than the minimum point of this range on certain dates during this period, as this information is
not publicly available or otherwise provided to the Company. |
(3) |
Based solely upon and qualified in its entirety with reference to, a notice provided to the Company by Harel Insurance Investments
& Financial Services Ltd. as of March 31, 2024. Based solely upon, and qualified in its entirety with reference to, information provided
to the Company by Harel Insurance Investments & Financial Services Ltd. and public filings, we believe the percentage of our ordinary
shares beneficially owned by Harel Insurance Investments & Financial Services Ltd. during the past three years has ranged between
4.7% and 7.4%, however there is no assurance this shareholder did not own fewer shares than the minimum point of this range on certain
dates during this period as this information is not publicly available or otherwise provided to the Company. |
(4) |
Based solely upon and qualified in its entirety with reference to, a notice provided to the Company by Senvest Management, LLC as
of March 31, 2024. Based solely upon, and qualified in its entirety with reference to, information provided to the Company by Senvest
Management, LLC and public filings, we believe the percentage of our ordinary shares beneficially owned by Senvest Management, LLC during
the past three years has ranged between 3.8% and 7.9%, however there is no assurance this shareholder did not own fewer shares than the
minimum point of this range on certain dates during this period as this information is not publicly available or otherwise provided to
the Company. |
(5) |
Based solely upon and qualified in its entirety with reference to, a notice provided to the Company by Clal Insurance Enterprises
Holdings Ltd. as of March 31, 2024. Based solely upon, and qualified in its entirety with reference to, information provided to the Company
by Clal Insurance Enterprises Holdings Ltd. and public filings, we believe the percentage of our ordinary shares beneficially owned by
Clal Insurance Enterprises Holdings Ltd. during the past three years has ranged between 3.5% and 6.1%, however there is no assurance this
shareholder did not own fewer shares than the minimum point of this range on certain dates during this period as this information is not
publicly available or otherwise provided to the Company. |
• |
amendments to our Articles of Association; |
• |
appointment, terms of engagement and termination of engagement of our independent auditors; |
• |
appointment and dismissal of external directors (if applicable); |
• |
approval of certain related party transactions and certain officer and director compensation; |
• |
increase or reduction of authorized share capital in accordance with the provisions of the Companies Law; |
• |
a merger; and |
• |
the exercise of the Board of Directors’ powers by the general meeting, if the Board of Directors is unable to exercise its
powers and the exercise of any of its powers is essential for Tower’s proper management. |
• |
Industrial companies meeting the criteria set out by the Investment Law for a “Preferred Income” of a “Preferred
Enterprise” (as defined below) will be eligible for reduced and flat corporate tax rates of 7.5% (currently, following the 2017
Amendment described below) or 16% in 2017 and thereafter, with the actual tax rates determined by the location of the enterprise in Israel.
The location of Tower's facilities in Israel (also referred to as “Zone A”) entitles it to benefit from a tax rate of 7.5%
on its Preferred Income. According to the 2011 Amendment, the tax incentives offered by the Investment Law are no longer dependent neither
on minimum qualified investments nor on foreign ownership. |
• |
A company can enjoy both government grants and tax benefits concurrently. Governmental grants will not necessarily be dependent on
the extent of enterprise’s investment in assets and/or equipment. |
• |
an individual citizen or resident of the United States; |
• |
a corporation created or organized in or under the laws of the United States or of any state of the United States or the District
of Columbia; |
• |
an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
• |
a trust if the trust has elected validly to be treated as a United States person for U.S. federal income tax purposes or if a U.S.
court is able to exercise primary supervision over the trust’s administration and one or more United States persons have the authority
to control all of the trust’s substantial decisions. |
• |
insurance companies; |
• |
dealers in stocks, securities or currencies; |
• |
financial institutions and financial services entities; |
• |
real estate investment trusts; |
• |
regulated investment companies; |
• |
persons that receive ordinary shares as compensation for the performance of services; |
• |
tax-exempt organizations; |
• |
persons that hold ordinary shares as a position in a straddle or as part of a hedging, conversion or other integrated instrument;
|
• |
individual retirement and other tax-deferred accounts; |
• |
expatriates of the United States; |
• |
persons (other than Non-U.S. Holders) having a functional currency other than the U.S. dollar; and |
• |
direct, indirect or constructive owners of 10% or more, by voting power or value, of us. |
• | (a) | the stock of that corporation with respect to which the dividends are paid is readily tradable on an established securities market in the U.S., or |
• | (b) | that corporation is eligible for benefits of a comprehensive income tax treaty with the U.S. which includes an information exchange program and is determined to be satisfactory by the U.S. Secretary of the Treasury. The Internal Revenue Service has determined that the U.S.-Israel Tax Treaty is satisfactory for this purpose. |
• |
that gain is effectively connected with the conduct by the Non-U.S. Holder of a trade or business in the United States, or
|
• |
in the case of any gain realized by an individual Non-U.S. Holder, that holder is present in the United States for 183 days or more
in the taxable year of the sale or exchange, and other conditions are met. |
• | (1) | a U.S. person; |
• | (2) | the government of the U.S. or the government of any state or political subdivision of any state (or any agency or instrumentality of any of these governmental units); |
• | (3) | a controlled foreign corporation; |
• | (4) | a foreign partnership that is either engaged in a U.S. trade or business or whose United States partners in the aggregate hold more than 50% of the income or capital interests in the partnership; |
• | (5) | a foreign person that derives 50% or more of its gross income for certain periods from the conduct of a trade or business in the U.S.; or |
• | (6) | a U.S. branch of a foreign bank or insurance company. |
2023 |
2022 |
|||||||
(US dollars in Thousands) |
||||||||
Audit Fees (1) |
816 |
819 |
||||||
Audit-Related Fees (2) |
0 |
58 |
||||||
Tax Fees (3) |
77 |
1 |
||||||
All Other Fees (4) |
11 |
-- |
||||||
904 |
878 |
• |
Distribution of certain reports to shareholders. As opposed to Nasdaq Listing Rule
5250(d), which requires listed issuers to make annual reports available to shareholders in one of a number of specific manners, Israeli
law does not require that we distribute annual reports, including our financial statements. As such, the generally accepted business practice
in Israel is to distribute such reports to shareholders through a public regulated distribution website. In addition to making such reports
available on a public regulated distribution website, our audited financial statements are available to our shareholders at our offices
and will only mail such reports to shareholders upon request. |
• |
Independent director meetings. Our Board has not adopted a policy of conducting regularly
scheduled meetings at which only our independent directors are present, as permitted by Israeli law. We do not follow the requirements
of Nasdaq Listing Rule 5605(b)(2). |
• |
Compensation of officers. We follow Israeli law and practice with respect to the approval
of compensation for our chief executive officer and other executive officers. While our compensation committee currently complies with
the provisions of the Nasdaq Listing Rules relating to composition requirements, Israeli law generally requires that the compensation
of the chief executive officer and all other executive officers be approved, or recommended to the board for approval, by the compensation
committee (with respect to the compensation of the chief executive officer and in certain other instances, shareholder approval is also
required). Israeli law may differ from the provisions provided for in Nasdaq Listing Rule 5605(d) (see Exhibit 2.1 to this annual report,
“Description of Securities”). |
• |
Director nomination process. While our corporate governance and nominating committee
currently complies with the provisions of the Nasdaq Listing Rules relating to composition requirements, the process under which director
nominees are selected, or recommended for the Board of Directors selection, may not be in full compliance with the applicable Nasdaq Listing
Rule 5605(e). Furthermore, although we have adopted a formal written corporate governance and nominating committee charter, there is no
requirement under the Companies Law to do so and the charter as adopted may not be in full compliance with the requirements under Nasdaq
Listing Rule 5605(e)(2). |
• |
Audit Committee Charter. Although we have adopted a formal written audit committee
charter, there is no requirement under the Companies Law to do so and the charter as adopted may not specify all the items enumerated
in Nasdaq Listing Rule 5605(c)(1). |
• |
Compensation Committee Charter. Although we have adopted a formal written compensation
committee charter, there is no requirement under the Companies Law to do so and the charter as adopted may not specify all the items enumerated
in Nasdaq Listing Rule 5605(d)(1). |
• |
Quorum requirements. Under our articles of association and as permitted under the Companies
Law, a quorum for any meeting of shareholders shall be the presence of at least two shareholders holding a combined 33% of our outstanding
ordinary shares, instead of 33 1/3% of the issued share capital required under Nasdaq Listing Rule 5620(c). If the meeting was adjourned
for lack of a quorum, if a quorum is not present at the adjourned meeting within half an hour of the time fixed for the commencement of
the adjourned meeting, the shareholders present, in person or by proxy, shall constitute a quorum. |
• |
Related Party Transactions. We review and approve all related party transactions in
accordance with the requirements and procedures for approval of related party acts and transactions set forth in Sections 268 to 275 the
Companies Law, which may not fully reflect the requirements of Nasdaq Listing Rule 5630. |
• |
Shareholder Approval. We seek shareholder approval for all corporate actions requiring
such approval under the requirements of the Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq
Listing Rule 5635. Under the Companies Law, shareholder approval is required (subject to certain limited exceptions) for, among other
things: (a) transactions with directors concerning the terms of their service (including indemnification, exemption, and insurance for
their service or for any other position that they may hold at a company), for which approvals of the compensation committee, board of
directors, and shareholders are all required (subject to exceptions) (see Exhibit 2.1 to this annual report, “Description of Securities”);
(b) extraordinary transactions with controlling shareholders of publicly held companies; (c) terms of office and employment or other engagement
of a controlling shareholder, if any, or such controlling shareholder’s relative; (d) approval of transactions with the chief executive
officer with respect to his or her compensation, or transactions with officers not in accordance with the approved compensation policy
(see Exhibit 2.1 to this annual report, “Description of Securities”); and (e) approval of the compensation policy for office
holders (within the meaning of the Companies Law) (see “Item 6 Directors, Senior Management and Employees–B. Compensation”).
In addition, under the Companies Law, a merger requires the approval of the shareholders of each of the merging companies. |
Page
|
|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID
|
F-2 - F-4
|
F-5
|
|
F-6
|
|
F-7
|
|
F-8
|
|
F-9 - F-10
|
|
F-11 - F-53
|
• |
We obtained the taxable income allocation used in calculating the income tax provision and tested that the taxable income allocation between Israel and corporate operations and the other subsidiaries is appropriate based on the specified services and margins determined in the Company's transfer pricing studies.
|
• |
We tested the effectiveness of controls over the Company’s process to allocate its taxable income between the different subsidiaries based on the Company's transfer pricing studies.
|
• |
We read and evaluated management’s documentation, including information obtained by management from external tax specialists that detailed the basis of the uncertain tax positions.
|
• |
With the assistance of our income tax specialists, we evaluated:
|
• |
The appropriateness of the transfer pricing analysis, including the transfer pricing methods and profit level indicators and ranges provided within the transfer pricing studies conducted by the Company’s external tax specialists.
|
• |
The appropriateness of the transfer pricing methodology implemented by management as provided in the transfer pricing studies.
|
• |
The relevant facts by reading the Company’s correspondence with the relevant tax authorities and any third-party advice obtained by the Company.
|
• |
The Company’s measurement of uncertain tax positions related to transfer pricing based on our knowledge of international and local income tax laws, as well as historical settlement activity from income tax authorities.
|
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED BALANCE SHEETS
|
(dollars and shares in thousands)
|
As of
|
||||||||
December 31,
|
||||||||
2023
|
2022
|
|||||||
ASSETS
|
||||||||
CURRENT ASSETS
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Short-term deposits
|
|
|
||||||
Marketable securities (*)
|
|
|
||||||
Trade accounts receivable
|
|
|
||||||
Inventories
|
|
|
||||||
Other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
LONG-TERM INVESTMENTS
|
|
|
||||||
PROPERTY AND EQUIPMENT, NET
|
|
|
||||||
INTANGIBLE ASSETS, NET
|
|
|
||||||
GOODWILL
|
|
|
||||||
DEFERRED TAX AND OTHER LONG-TERM ASSETS, NET
|
|
|
||||||
TOTAL ASSETS
|
$
|
|
$
|
|
||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
CURRENT LIABILITIES
|
||||||||
Current maturities of long-term debt
|
$
|
|
$
|
|
||||
Trade accounts payable
|
|
|
||||||
Deferred revenue and customers' advances
|
|
|
||||||
Employee related liabilities
|
|
|
||||||
Other current liabilities
|
|
|
||||||
Total current liabilities
|
|
|
||||||
LONG-TERM DEBT
|
|
|
||||||
LONG-TERM CUSTOMERS' ADVANCES
|
|
|
||||||
EMPLOYEE RELATED LIABILITIES
|
|
|
||||||
DEFERRED TAX AND OTHER LONG-TERM LIABILITIES
|
|
|
||||||
TOTAL LIABILITIES
|
|
|
||||||
Ordinary shares of NIS
|
|
|
||||||
|
||||||||
|
||||||||
|
||||||||
Additional paid-in capital
|
|
|
||||||
Cumulative stock based compensation
|
|
|
||||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Retained earnings (accumulated deficit)
|
|
(
|
)
|
|||||
|
|
|||||||
Treasury stock, at cost -
|
(
|
)
|
(
|
)
|
||||
THE COMPANY'S SHAREHOLDERS' EQUITY
|
|
|
||||||
Non-controlling interest
|
(
|
)
|
(
|
)
|
||||
TOTAL SHAREHOLDERS' EQUITY
|
|
|
||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
|
$
|
|
$
|
|
F - 5
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(dollars and shares in thousands, except per share data)
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
REVENUES
|
$
|
|
$
|
|
$
|
|
||||||
COST OF REVENUES
|
|
|
|
|||||||||
GROSS PROFIT
|
|
|
|
|||||||||
OPERATING COSTS AND EXPENSES:
|
||||||||||||
Research and development
|
|
|
|
|||||||||
Marketing, general and administrative
|
|
|
|
|||||||||
Restructuring gain from sale of machinery and equipment, net
|
(
|
)
|
(
|
)
|
|
|||||||
Restructuring expense
|
|
|
|
|||||||||
Merger-contract termination fee, net
|
(
|
)
|
|
|
||||||||
(
|
)
|
|
|
|||||||||
OPERATING PROFIT
|
|
|
|
|||||||||
FINANCING INCOME (EXPENSE), NET
|
|
(
|
)
|
(
|
)
|
|||||||
OTHER INCOME (EXPENSE), NET
|
|
(
|
)
|
|
||||||||
PROFIT BEFORE INCOME TAX
|
|
|
|
|||||||||
INCOME TAX EXPENSE, NET
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
NET PROFIT
|
|
|
|
|||||||||
Net income attributable to non-controlling interest
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
NET PROFIT ATTRIBUTABLE TO THE COMPANY
|
$
|
|
$
|
|
$
|
|
||||||
BASIC EARNINGS PER SHARE
|
||||||||||||
Earnings per share
|
$
|
|
$
|
|
$
|
|
||||||
Weighted average number of shares
|
|
|
|
|||||||||
DILUTED EARNINGS PER ORDINARY SHARE:
|
||||||||||||
Earnings per share
|
$
|
|
$
|
|
$
|
|
||||||
Net profit used for diluted earnings per share
|
|
$
|
|
$
|
|
|||||||
Weighted average number of ordinary shares outstanding
|
||||||||||||
used for diluted earnings per share
|
|
|
|
See notes to consolidated financial statements.
|
F - 6
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
(dollars in thousands)
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Net profit
|
$
|
|
$
|
|
$
|
|
||||||
Other comprehensive income, net of tax:
|
||||||||||||
Foreign currency translation adjustment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in employees plan assets and benefit obligations, net of taxes
|
(
|
)
|
(
|
)
|
|
|||||||
Unrealized gain (loss) on derivatives and marketable securities
|
|
(
|
)
|
(
|
)
|
|||||||
Comprehensive income
|
|
|
|
|||||||||
Comprehensive loss attributable to non-controlling interest
|
|
|
|
|||||||||
Comprehensive income attributable to the Company
|
$
|
|
$
|
|
$
|
|
See notes to consolidated financial statements.
|
F - 7
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
|
(dollars and share data in thousands)
|
THE COMPANY'S SHAREHOLDERS' EQUITY
|
||||||||||||||||||||||||||||||||||||||||||||
Accumulated
|
Foreign
|
Retained
|
||||||||||||||||||||||||||||||||||||||||||
Ordinary
|
Ordinary
|
Additional
|
other
|
currency
|
earnings
|
Non
|
||||||||||||||||||||||||||||||||||||||
shares
|
shares
|
paid-in
|
Unearned
|
comprehensive
|
translation
|
(accumulated
|
Treasury
|
Comprehensive
|
controlling
|
|||||||||||||||||||||||||||||||||||
issued
|
amount
|
capital
|
compensation
|
income (loss)
|
adjustments
|
deficit)
|
stock
|
income
|
interest
|
Total
|
||||||||||||||||||||||||||||||||||
BALANCE AS OF JANUARY 1, 2021
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||||||||||
Changes during the year ended December 31, 2021:
|
||||||||||||||||||||||||||||||||||||||||||||
Exercise of options and RSUs
|
|
|
(
|
)
|
|
|||||||||||||||||||||||||||||||||||||||
Employee stock-based compensation
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income:
|
||||||||||||||||||||||||||||||||||||||||||||
Profit
|
|
$
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||
Change in employees plan assets and benefit obligations
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
Unrealized loss on derivatives and marketable securities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||
Comprehensive income
|
$
|
|
||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2021
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|||||||||||||||||||||||||||||
Changes during the year ended December 31, 2022:
|
||||||||||||||||||||||||||||||||||||||||||||
Proceeds from an investment in a subsidiary
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Exercise of options and RSUs
|
|
|
(
|
)
|
|
|||||||||||||||||||||||||||||||||||||||
Employee stock-based compensation
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income:
|
||||||||||||||||||||||||||||||||||||||||||||
Profit
|
|
$
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||
Change in employees plan assets and benefit obligations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||
Unrealized loss on derivatives and marketable securities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||
Comprehensive income
|
$
|
|
||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2022
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|||||||||||||||||||||||||||||
Changes during the year ended December 31, 2023:
|
||||||||||||||||||||||||||||||||||||||||||||
Proceeds from an investment in a subsidiary
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Exercise of options and RSUs
|
|
|
(
|
)
|
|
|||||||||||||||||||||||||||||||||||||||
Employee stock-based compensation
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income:
|
||||||||||||||||||||||||||||||||||||||||||||
Profit
|
|
$
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||
Change in employees plan assets and benefit obligations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||
Unrealized gain on derivatives and marketable securities
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
Comprehensive income
|
$
|
|
||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2023
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||||||||||||
OUTSTANDING SHARES, NET OF TREASURY STOCK AS OF DECEMBER 31, 2023
|
|
See notes to consolidated financial statements.
|
F - 8
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(dollars in thousands)
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
CASH FLOWS - OPERATING ACTIVITIES
|
||||||||||||
Net profit for the period
|
$
|
|
$
|
|
$
|
|
||||||
Adjustments to reconcile net profit for the period
to net cash provided by operating activities:
|
||||||||||||
Income and expense items not involving cash flows:
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Effect of exchange rate differences and fair value adjustment
|
(
|
)
|
|
|
||||||||
Other expense (income), net
|
(
|
)
|
|
(
|
)
|
|||||||
Changes in assets and liabilities:
|
||||||||||||
Trade accounts receivable
|
(
|
)
|
(
|
)
|
|
|||||||
Other current assets
|
(
|
)
|
|
(
|
)
|
|||||||
Inventories
|
|
(
|
)
|
(
|
)
|
|||||||
Trade accounts payable
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Deferred revenue and customers' advances
|
(
|
)
|
(
|
)
|
|
|||||||
Employee related liabilities and other current liabilities
|
(
|
)
|
|
|
||||||||
Long-term employee related liabilities
|
(
|
)
|
|
(
|
)
|
|||||||
Deferred tax, net and other long-term liabilities
|
|
|
(
|
)
|
||||||||
Net cash provided by operating activities
|
|
|
|
|||||||||
CASH FLOWS - INVESTING ACTIVITIES
|
||||||||||||
Investments in property and equipment, net
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds related to sale and disposal of property and equipment
|
|
|
|
|||||||||
Proceeds from investment realization
|
|
|
|
|||||||||
Investments in other assets
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Deposits and marketable securities, net
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
CASH FLOWS - FINANCING ACTIVITIES
|
||||||||||||
Proceeds from an investment in a subsidiary
|
|
|
|
|||||||||
Exercise of options, net
|
|
|
|
|||||||||
Proceeds from loans
|
|
|
|
|||||||||
Loans repayment
|
|
|
(
|
)
|
||||||||
Principal payments on account of capital lease obligation
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Debentures repayment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash used in financing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGE
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(
|
)
|
|
(
|
)
|
|||||||
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD
|
|
|
|
|||||||||
CASH AND CASH EQUIVALENTS - END OF PERIOD
|
$
|
|
$
|
|
$
|
|
See notes to consolidated financial statements.
|
F - 9
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(dollars in thousands)
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
NON-CASH ACTIVITIES:
|
||||||||||||
Investments in property and equipment
|
$
|
|
$
|
|
$
|
$
|
||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
|
||||||||||||
Cash received during the period from interest
|
$
|
|
$
|
|
$
|
$
|
||||||
Cash paid during the period for interest
|
$
|
|
$
|
|
$
|
$
|
||||||
Cash paid for income taxes, net during the period
|
$
|
|
$
|
|
$
|
$
|
See notes to consolidated financial statements.
|
F - 10
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 11
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 12
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
F - 13
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
• |
Buildings and building improvements, including facility infrastructure:
|
• |
Machinery and equipment, software and hardware:
|
F - 14
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 15
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 16
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 17
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 18
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 19
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 20
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
||||||
Raw materials
|
$
|
|
$
|
|
||||
Work in process
|
|
|
||||||
Finished goods
|
|
|
||||||
$
|
|
$
|
|
F - 21
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
||||||
Direct and indirect tax receivables
|
$
|
|
$
|
|
||||
Prepaid expenses
|
|
|
||||||
Receivables from hedging transactions - see Notes 10, 12A and 12D
|
|
|
||||||
Other receivables
|
|
|
||||||
$
|
|
$
|
|
Details
|
2023
|
2022
|
||||||
Investments in privately held companies
|
$
|
|
$
|
|
||||
Severance-pay funds
|
|
|
||||||
$
|
|
$
|
|
Details
|
2023
|
2022
|
||||||
Original cost: (*)
|
||||||||
Land and buildings, including facility infrastructure
|
$
|
|
$
|
|
||||
Machinery and equipment
|
|
|
||||||
|
|
|||||||
Accumulated depreciation:
|
||||||||
Buildings, including facility infrastructure
|
(
|
)
|
(
|
)
|
||||
Machinery and equipment
|
(
|
)
|
(
|
)
|
||||
(
|
)
|
(
|
)
|
|||||
$
|
|
$
|
|
F - 22
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
Useful life
(years)
|
Cost
|
Accumulated Amortization
|
Net
|
||||||||||||
Facilities’ lease
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||
Technologies
|
|
|
(
|
)
|
|
|||||||||||
Customer relationships
|
|
|
(
|
)
|
|
|||||||||||
Total identifiable intangible assets
|
$
|
|
$
|
(
|
)
|
$
|
|
Details
|
Useful life
(years)
|
Cost
|
Accumulated Amortization
|
Net
|
||||||||||||
Facilities’ lease
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||
Technologies
|
|
|
(
|
)
|
|
|||||||||||
Customer relationships
|
|
|
(
|
)
|
|
|||||||||||
Total identifiable intangible assets
|
$
|
|
$
|
(
|
)
|
$
|
|
Details
|
2023
|
2022
|
||||||
Long-term prepaid expenses
|
$
|
|
$
|
|
||||
ROU - assets under operating leases
|
|
|
||||||
Prepaid long-term land lease, net
|
|
|
||||||
Deferred tax asset (see Note 19)
|
|
|
||||||
$
|
|
$
|
|
Details
|
2023
|
2022
|
||||||
Tax payables
|
$
|
|
$
|
|
||||
Hedging transactions related payables
|
|
|
||||||
Interest payable on debt
|
|
|
||||||
Proceeds on account of machinery and equipment to be sold in relation to restructuring (see also note 14B2)
|
|
|
||||||
Others
|
|
|
||||||
$
|
|
$
|
|
F - 23
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
||||||
Long-term JPY loans - principal amount - see Notes 11B and 11C below
|
$
|
|
$
|
|
||||
- see Note 11D below
|
|
|
||||||
Operating leases - see Note 11E below
|
|
|
||||||
Less - current maturities
|
(
|
)
|
(
|
)
|
||||
$
|
|
$
|
|
Details
|
Interest
Rate
|
2024
|
2025
|
2026
|
2027
|
Total
|
||||||||||||||||||
Long-term 2021 JPY loan
|
|
%
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Long-term 2023 JPY loan
|
|
%
|
|
|
|
|
|
|||||||||||||||||
Total long-term JPY loans
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
F - 24
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Fiscal Year
|
Amount ($)
|
|||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
2028
|
|
|||
2029 and on
|
|
|||
Total
|
|
|||
Less - imputed interest
|
(
|
)
|
||
Total
|
$
|
|
F - 25
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
Classification in the Consolidated Balance Sheets
|
December 31, 2023
|
December 31, 2022
|
|||||||
ROU - assets under operating leases
|
|
$
|
|
$
|
|
|||||
Lease liabilities:
|
||||||||||
Current operating lease liabilities
|
|
$
|
|
$
|
|
|||||
Long-term operating lease liabilities
|
|
|
|
|||||||
Total operating lease liabilities
|
$
|
|
$
|
|
||||||
Weighted average remaining lease term (years)
|
|
|
||||||||
Weighted average discount rate
|
|
%
|
|
%
|
Fiscal Year
|
Amount ($)
|
|||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
Total
|
|
|||
Less - imputed interest
|
(
|
)
|
||
Total
|
$
|
|
F - 26
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 27
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 28
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 29
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
December 31, 2023
|
Quoted prices in active market
(Level 1)
|
Significant other observable inputs
(Level 2)
|
Significant unobservable inputs
(Level 3)
|
||||||||||||
Privately held companies
|
|
|
|
|
||||||||||||
Marketable securities held for sale
|
|
|
|
|
||||||||||||
Foreign exchange forward and cylinders - net asset position
|
|
|
|
|
||||||||||||
$
|
|
$
|
|
$
|
|
$
|
|
Details
|
December 31, 2022
|
Quoted prices in active market
(Level 1)
|
Significant other observable inputs
(Level 2)
|
Significant unobservable inputs
(Level 3)
|
||||||||||||
Cross-currency swap - net asset position
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Privately held companies
|
|
|
|
|
||||||||||||
Marketable securities held for sale
|
|
|
|
|
||||||||||||
Foreign exchange forward and cylinders - net liability position
|
(
|
)
|
|
(
|
)
|
|
||||||||||
$
|
|
$
|
|
$
|
|
$
|
|
F - 30
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
Amortized
Cost (*)
|
Gross unrealized gains
|
Gross unrealized losses
|
Estimated fair value
|
||||||||||||
Corporate bonds
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
Government bonds
|
|
|
(
|
)
|
|
|||||||||||
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
Details
|
Amortized Cost
|
Estimated fair value
|
||||||
Due within one year
|
$
|
|
$
|
|
||||
Due within 2-5 years
|
|
|
||||||
Due after 5 years
|
|
|
||||||
$
|
|
$
|
|
Details
|
Amortized
Cost (*)
|
Gross unrealized gains
|
Gross unrealized losses
|
Estimated fair
value
|
||||||||||||
Corporate bonds
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
Government bonds
|
|
|
(
|
)
|
|
|||||||||||
Municipal bonds
|
|
|
(
|
)
|
|
|||||||||||
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
F - 31
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
Amortized Cost
|
Estimated fair value
|
||||||
Due within one year
|
$
|
|
$
|
|
||||
Due within 2-5 years
|
|
|
||||||
Due after 5 years
|
|
|
||||||
$
|
|
$
|
|
December 31, 2023
|
||||||||||||||||||||||||
Investments with continuous unrealized losses for less than twelve months
|
Investments with continuous unrealized losses for twelve months or more
|
Total investments with continuous unrealized losses
|
||||||||||||||||||||||
Details
|
Fair value
|
Unrealized losses
|
Fair value
|
Unrealized losses
|
Fair value
|
Unrealized losses
|
||||||||||||||||||
Corporate bonds
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||||||
Government bonds
|
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||
Total
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
December 31, 2022 | ||||||||||||||||||||||||
Investments with continuous unrealized losses for less than twelve months
|
Investments with continuous unrealized losses for twelve months or more
|
Total investments with continuous unrealized losses
|
||||||||||||||||||||||
Details
|
Fair value
|
Unrealized losses
|
Fair value
|
Unrealized losses
|
Fair value
|
Unrealized losses
|
||||||||||||||||||
Corporate bonds
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||||||
Government bonds
|
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||
Municipal bonds
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||
Total
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
F - 32
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 33
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Net periodic benefit cost:
|
||||||||||||
Service cost
|
$
|
|
$
|
|
$
|
|
||||||
Interest cost
|
|
|
|
|||||||||
Amortization of prior service costs
|
|
|
|
|||||||||
Amortization of net gain |
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total net periodic benefit cost
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Other changes in plan assets and benefits obligations recognized in other comprehensive income:
|
||||||||||||
Prior service cost for the period
|
$
|
|
$
|
|
$
|
|
||||||
Net gain for the period
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Amortization of prior service costs
|
|
|
|
|||||||||
Amortization of net gain
|
|
|
|
|||||||||
Total recognized in other comprehensive income
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Total recognized in net periodic benefit cost and other comprehensive income |
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||
Weighted average assumptions used:
|
||||||||||||
Discount rate
|
|
%
|
|
%
|
|
%
|
||||||
Expected return on plan assets
|
|
|
|
|||||||||
Rate of compensation increases
|
|
|
|
|||||||||
Assumed health care cost trend rates:
|
||||||||||||
Health care cost trend rate assumed for current year (pre-65/post-65 Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Health care cost trend rate assumed for current year (pre-65/post-65 Non-Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Ultimate rate (pre-65/post-65)
|
|
%
|
|
%
|
|
%
|
||||||
Year the ultimate rate is reached (pre-65/post-65) |
|
|
|
|||||||||
Measurement date
|
|
|
|
F - 34
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Change in medical plan related benefit obligation:
|
||||||||||||
Medical plan related benefit obligation at beginning of period
|
$
|
|
$
|
|
$
|
|
||||||
Service cost
|
|
|
|
|||||||||
Interest cost
|
|
|
|
|||||||||
Benefits paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in medical plan provisions
|
|
|
|
|||||||||
Actuarial gain, net |
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Benefit medical plan related obligation end of period
|
$
|
|
$
|
|
$
|
|
||||||
Change in plan assets:
|
||||||||||||
Fair value of plan assets at beginning of period
|
$
|
|
$
|
|
$
|
|
||||||
Employer contribution
|
|
|
|
|||||||||
Benefits paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Fair value of plan assets at end of period
|
$
|
|
$
|
|
$
|
|
||||||
Medical plan related net funding
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
F - 35
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Amounts recognized in statement of financial position:
|
||||||||||||
Current liabilities
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Non-current liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net amount recognized
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Weighted average assumptions used:
|
||||||||||||
Discount rate
|
|
%
|
|
%
|
|
%
|
||||||
Rate of compensation increases
|
|
|
|
|||||||||
Assumed health care cost trend rates:
|
||||||||||||
Health care cost trend rate assumed for next year (pre-65/post-65 Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Health care cost trend rate assumed for next year (pre-65/post-65 Non-Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Ultimate rate (pre-65/post-65 Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Ultimate rate (pre-65/post-65 Non-Medicare Advantage)
|
|
%
|
|
%
|
|
%
|
||||||
Year the ultimate rate is reached (pre-65/post-65 Medicare Advantage)
|
|
|
|
|||||||||
Year the ultimate rate is reached (pre-65/post-65 Non-Medicare Advantage) |
|
|
|
Fiscal Year
|
Other Benefits
|
|||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
2028
|
|
|||
2029 - 2033
|
$
|
|
Description of Significant Gains and Losses in Obligations:
F - 36
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Net periodic benefit cost:
|
||||||||||||
Interest cost
|
$
|
|
$
|
|
$
|
|
||||||
Expected return on plan assets
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Expected administrative expenses
|
|
|
|
|||||||||
Amortization of prior service costs
|
|
|
|
|||||||||
Amortization of net loss
|
|
|
|
|||||||||
Total net periodic benefit cost
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||
Other changes in plan assets and benefits obligations recognized in other comprehensive income:
|
||||||||||||
Prior service cost for the period
|
$
|
|
$
|
|
$
|
|
||||||
Net loss (gain) for the period
|
|
|
(
|
)
|
||||||||
Amortization of prior service costs
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Amortization of net gain
|
(
|
)
|
|
(
|
)
|
|||||||
Total recognized loss (gain) in other comprehensive income = |
$
|
|
$
|
|
$
|
(
|
)
|
|||||
Total recognized in net periodic benefit cost (gain) and other comprehensive income |
$
|
|
$
|
|
$
|
(
|
)
|
|||||
Weighted average assumptions used:
|
||||||||||||
Discount rate
|
|
%
|
|
%
|
|
%
|
||||||
Expected return on plan assets
|
|
%
|
|
%
|
|
%
|
||||||
Rate of compensation increases
|
|
|
|
F - 37
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Change in benefit obligation:
|
||||||||||||
Benefit obligation at beginning of period
|
$
|
|
$
|
|
$
|
|
||||||
Interest cost
|
|
|
|
|||||||||
Benefits paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in plan provisions
|
|
|
|
|||||||||
Actuarial loss (gain)
|
|
(
|
)
|
(
|
)
|
|||||||
Benefit obligation end of period
|
$
|
|
$
|
|
$
|
|
||||||
Change in plan assets:
|
||||||||||||
Fair value of plan assets at beginning of period
|
$
|
|
$
|
|
$
|
|
||||||
Actual return on plan assets
|
|
(
|
)
|
|
||||||||
Employer contribution
|
|
|
|
|||||||||
Expenses paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Benefits paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Fair value of plan assets at end of period
|
$
|
|
$
|
|
$
|
|
||||||
Funded Status
|
$
|
|
$
|
|
$
|
|
||||||
Amounts recognized in statement of financial position:
|
||||||||||||
Non-current assets
|
$
|
|
$
|
|
$
|
|
||||||
Non-current liabilities
|
|
|
|
|||||||||
Net amount recognized
|
$
|
|
$
|
|
$
|
|
||||||
Weighted average assumptions used:
|
||||||||||||
Discount rate
|
|
%
|
|
%
|
|
%
|
||||||
Rate of compensation increases
|
|
|
|
F - 38
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Fiscal Year
|
Other Benefits
|
|||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
2028
|
|
|||
2029 - 2033
|
$
|
|
Details
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Investments in commingled funds
|
$
|
|
$
|
|
$
|
|
||||||
Total plan assets at fair value
|
$
|
|
$
|
|
$
|
|
Details
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Investments in commingled funds
|
$
|
|
$
|
|
$
|
|
||||||
Total plan assets at fair value
|
$
|
|
$
|
|
$
|
|
Asset Category
|
December 31, 2023
|
Target allocation 2024
|
||||||
Equity securities
|
|
%
|
|
%
|
||||
Debt securities
|
|
%
|
|
%
|
||||
Total
|
|
%
|
|
%
|
F - 39
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 40
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 14: COMMITMENTS AND CONTINGENCIES (continued)
Details
|
Asset disposal accrual
|
Other Restructuring costs accrual
|
||||||
Accrued balance as of January 1, 2022
|
$
|
|
$
|
|
||||
Expenses accrued
|
|
|
||||||
Accruals related to assets
|
|
|
||||||
Cash payments
|
(
|
)
|
(
|
)
|
||||
Accrued balance as of December 31, 2022
|
$
|
|
$
|
|
||||
Expenses accrued
|
|
|
||||||
Accruals related to assets
|
(
|
)
|
(
|
)
|
||||
Cash payments
|
(
|
)
|
(
|
)
|
||||
Accrued balance as of December 31, 2023
|
$
|
|
$
|
|
F - 41
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 14: COMMITMENTS AND CONTINGENCIES (continued)
NOTE 15: SHAREHOLDERS’ EQUITY
F - 42
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 15: SHAREHOLDERS’ EQUITY (continued)
F - 43
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 15: SHAREHOLDERS’ EQUITY (continued)
F - 44
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
NOTE 15: SHAREHOLDERS’ EQUITY (continued)
2023
|
2022
|
2021
|
||||||||||||||||||||||
Details
|
Number of RSUs
|
Weighted average fair value
|
Number of RSUs
|
Weighted average fair value
|
Number of RSUs
|
Weighted average fair value
|
||||||||||||||||||
Outstanding as of beginning of year
|
|
$
|
|
|
$
|
|
|
$
|
|
|||||||||||||||
Granted
|
|
$
|
|
|
$
|
|
|
$
|
|
|||||||||||||||
Converted
|
(
|
)
|
$
|
|
(
|
)
|
$
|
|
(
|
)
|
$
|
|
||||||||||||
Forfeited
|
(
|
)
|
$
|
|
(
|
)
|
$
|
|
(
|
)
|
$
|
|
||||||||||||
Outstanding as of end of year (*)
|
|
$
|
|
|
$
|
|
|
$
|
|
Details for the year ended December 31
|
2023
|
2022
|
2021
|
|||||||||
The intrinsic value of converted RSUs
|
$
|
|
$
|
|
$
|
|
||||||
The original fair value of converted RSUs
|
$
|
|
$
|
|
$
|
|
Details
|
2023
|
2022
|
2021
|
|||||||||
Cost of goods
|
$
|
|
$
|
|
$
|
|
||||||
Research and development, net
|
|
|
|
|||||||||
Marketing, general and administrative
|
|
|
|
|||||||||
Total stock-based compensation expense
|
$
|
|
$
|
|
$
|
|
C. Treasury Stock
F - 45
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
USA
|
|
%
|
|
%
|
|
%
|
||||||
Japan
|
|
|
|
|||||||||
Asia (other than Japan)
|
|
|
|
|||||||||
Europe
|
|
|
|
|||||||||
Total
|
|
%
|
|
%
|
|
%
|
Details
|
2023
|
2022
|
||||||
Israel
|
$
|
|
$
|
|
||||
United States
|
|
|
||||||
Europe
|
|
|
||||||
Japan
|
|
|
||||||
$
|
|
$
|
|
F - 46
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Customer A
|
|
%
|
|
%
|
|
%
|
||||||
Customer B
|
|
|
|
|||||||||
Other customers *
|
|
|
|
* |
|
Details
|
2023
|
2022
|
2021
|
|||||||||
Interest expense
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Interest income
|
|
|
|
|||||||||
Series G Debentures amortization, exchange rate and hedging transactions related results
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Exchange rate and hedging transactions related results
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Marketable securities fair value adjustments
|
|
(
|
)
|
|
||||||||
Bank fees and others
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
F - 47
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
|||||||
Long-term investment
|
Equity investment in a limited partnership
|
$
|
|
$
|
|
Details
|
Description of the transactions
|
2023
|
2022
|
2021
|
||||||||||
General and administrative expense
|
Directors’ fees and reimbursement to directors
|
$
|
|
$
|
|
$
|
|
F - 48
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
2021
|
|||||||||
Current tax expense:
|
||||||||||||
Foreign
|
$
|
|
$
|
|
$
|
|
||||||
Deferred tax expense (benefit):
|
||||||||||||
Local
|
|
|
|
|||||||||
Foreign
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Income tax expense, net
|
$
|
|
$
|
|
$
|
|
Details
|
2023
|
2022
|
2021
|
|||||||||
Profit before taxes:
|
||||||||||||
Local
|
$
|
|
$
|
|
$
|
|
||||||
Foreign
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total profit before taxes
|
$
|
|
$
|
|
$
|
|
F - 49
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
2023
|
2022
|
||||||
Deferred tax asset and liability - long-term:
|
||||||||
Deferred tax assets:
|
||||||||
Net operating loss carryforward
|
$
|
|
$
|
|
||||
Employees compensation
|
|
|
||||||
Accruals and allowances
|
|
|
||||||
Research and development credit
|
|
|
||||||
Research and development - Section 174
|
|
|
||||||
Lease liabilities
|
|
|
||||||
Others
|
|
|
||||||
|
|
|||||||
Valuation allowance, see Note 19F below
|
(
|
)
|
(
|
)
|
||||
Deferred tax assets
|
$
|
|
$
|
|
||||
Deferred tax liabilities - long-term:
|
||||||||
Depreciation and amortization
|
$
|
(
|
)
|
$
|
(
|
)
|
||
ROU - assets under operating leases
|
(
|
)
|
(
|
)
|
||||
Others
|
(
|
)
|
|
|||||
Deferred tax liabilities
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Presented in long term deferred tax assets
|
$
|
|
$
|
|
||||
Presented in long term deferred tax liabilities
|
$
|
(
|
)
|
$
|
(
|
)
|
F - 50
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
Details
|
Unrecognized tax benefits
|
|||
Balance as of January 1, 2023
|
$
|
|
||
Additions for tax positions of current year
|
|
|||
Reduction due to statute of limitations of prior years
|
|
|||
Balance as of December 31, 2023
|
$
|
|
Details
|
Unrecognized tax benefits
|
|||
Balance as of January 1, 2022
|
$
|
|
||
Additions for tax positions of current year
|
|
|||
Reduction due to statute of limitations of prior years
|
|
|||
Balance as of December 31, 2022
|
$
|
|
Details
|
Unrecognized tax benefits
|
|||
Balance as of January 1, 2021
|
$
|
|
||
Additions for tax positions of current year
|
|
|||
Reduction due to statute of limitations of prior years
|
(
|
)
|
||
Balance as of December 31, 2021
|
$
|
|
Details
|
2023
|
2022
|
2021
|
|||||||||
Tax expense computed at statutory rates, see (*) below
|
$
|
|
$
|
|
$
|
|
||||||
Effect of different tax rates in different jurisdictions and Preferred Enterprise Benefit
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in valuation allowance, see Note 19F below
|
|
|
|
|||||||||
Permanent differences and other, net
|
|
(
|
)
|
(
|
)
|
|||||||
Income tax expense
|
$
|
|
$
|
|
$
|
|
F - 51
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 52
TOWER SEMICONDUCTOR LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2023
(dollars in thousands, except per share data)
F - 53
• |
information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and
|
• |
all other important information pertaining to any such action.
|
• |
refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;
|
• |
refrain from any activity that is competitive with the company;
|
• |
refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and
|
• |
disclose to the company any information or documents relating to the company’s affairs which the office holder received as a result of his or her position as an office
holder.
|
• |
at least a majority of the shares held by all shareholders who are not controlling shareholders and shareholders who do not have a personal interest in the matter,
present and voting on the matter at such meeting, are voted in favor of the compensation package, excluding abstentions; or
|
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter, who vote against the compensation
package does not exceed two percent (2%) of the aggregate voting rights in the Company.
|
• |
any amendment to the Articles of Association;
|
• |
an increase of the company’s authorized share capital;
|
• |
a merger; or
|
• |
approval of interested party transactions and act of office holders that require shareholder approval.
|
• |
the securities issued amount to 20% or more of the company’s outstanding voting rights before the issuance;
|
• |
some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and
|
• |
the transaction will increase the relative holdings of a shareholder who holds 5% or more of the company’s outstanding share capital or voting rights or will cause any
person to become, as a result of the issuance, a holder of more than 5% of the company’s outstanding share capital or voting rights.
|
1. |
Definitions. In addition to the terms defined above and elsewhere in this Agreement, the following terms will have the meanings set forth below:
|
1.1 |
“CNDA” means the Corporate Non-Disclosure Agreement entered into by the Parties dated July 29, 2002 (CNDA No. [***]).
|
1.2 |
“Intel Facility” means Intel’s fab facility (Fab 11x) located in Rio Rancho, New Mexico.
|
1.3 |
“M-RUNDA” means the Master Restricted Use Non-Disclosure Agreement entered into by the Parties dated November 29, 2022 (M-RUNDA No. [***]).
|
1.4 |
“Non-Production Wafers” means Wafers that are not intended to be sold as a fully-qualified product, including engineering, pre-qualification, and Pre-Production Wafers.
|
1.5 |
“Pre-Production Wafers” means Wafers manufactured by Intel prior to Technology Qualification.
|
1.6 |
“Technology Qualification” means the qualification of the process technology for each type of Tower Product as described in Exhibit 2.
|
1.7 |
“Tower’s Property” means all drawings, specifications, recipes and technical information, and any other property (including any intellectual property embodied therein and any property of Tower’s
customers) furnished to Intel by Tower in connection with a Technology Qualification.
|
1.8 |
“Tower Tools” is defined in Exhibit 1, Section 8 below. Intel will periodically provide Tower with an updated list of the Tower Tools.
|
1.9 |
“Starting Material” means the substrate material used for the fabrication of integrated circuits that Tower will provide to Intel, and that Intel will use to manufacture the Tower Products (as
defined in Exhibit 1 and more fully described in Exhibit 2).
|
1.10 |
Any reference to ‘days’ in this agreement, absent specific language to the contrary will mean calendar days. When the term ‘business days’ is used it will be mean days of business of the party for whom the obligation applies.
|
2. |
Scope of Services. The Parties have agreed that during the term of this Agreement Intel will provide its services in accordance with the Foundry Product Attachment Scope of Services attached as
Exhibit 1 (“Project Description”) and the Statement of Work (“SOW”) attached as Exhibit 2 hereto (collectively, the “Services”).
The Project Description and SOW may be amended from time to time by the Parties’ written mutual agreement.
|
3. |
Delivery. Intel shall deliver to Tower the finished Tower Products in accordance with Exhibit 1 (Foundry Product Attachment).
|
4. |
Prices and Payment.
|
4.1 |
The agreed upon prices for the Tower Products, Services and other remuneration to be paid to Intel are as set forth in the Project Description.
|
4.2 |
All payments to Intel will be due at Intel’s bank [***]) calendar days from date of receipt by Tower of Intel’s invoice. Intel will deliver the Tower Products to Tower at Intel’s dock under [***] (Incoterms 2020).
|
5. |
Confidentiality. All Confidential Information (as defined in the CNDA) of each Party disclosed in the course of performance of this Agreement will be subject to the terms set forth in the CNDA and
the M-RUNDA, as appropriate. The existence and terms of this Agreement is Tower’s and Intel’s Confidential Information and may not be disclosed by a Party to a third party absent written permission from the other Party unless the disclosure
is required by applicable law or stock regulation, in which case the disclosing Party must provide reasonable advance notice and opportunity to comment to the other Party prior to the disclosure.
|
6. |
Limited Warranty.
|
6.1 |
Intel warrants that for a period of [***] from the date the Tower Products are delivered by Intel to Tower (“Warranty Period”): (i) the Tower Products will be processed in conformance with Tower’s
applicable process specifications in accordance with Tower’s manufacturing procedures, specifications and acceptance criteria set forth in the SOW; and (ii) the Tower Products are free of liens and encumbrances (other than any that may have
been placed upon them by Tower or Tower’s creditors) (the “Warranty”). Wafers which are Non-Production Wafers, or which have been subject (other than by Intel or Intel’s subcontractors) to abuse,
misuse, accident, alteration, neglect, electromigration effects or other conditions outside specifications, radiation-induced damage, unauthorized or improper repair or improper application are not covered by the Warranty. The Warranty does
not cover damage resulting from environmental or externally induced degradation. Intel will not be responsible for claims pursuant to this Warranty where the failure of the Warranty was caused by: (i) acts not performed by Intel or Intel’s
subcontractors; (ii) design or application; or (iii) the combination of Tower Products with other products and/or things, if such combination was the cause of the failure.
|
6.2 |
Tower Products delivered by Intel to Tower are not intended for use in and no warranty is made with respect to applications where failure to perform can reasonably be expected to result in significant injury (including, without limitation,
navigation, weaponry, aviation or nuclear equipment, or for surgical implant or to support or sustain life) and Tower will indemnify and hold harmless Intel, and at Intel’s option, defend Intel, from all claims, damages and liabilities
arising out of any such matters.
|
6.3 |
If any warranted Tower Products fail to conform to the Warranty, Intel’s sole and exclusive liability will be, at Intel’s option (provided however that Tower will not be required to accept repaired or replacement Tower Products if Tower no
longer has a need for such Tower Products and in such case Intel would provide Tower with credit), to repair, replace or credit Tower’s account with an amount equal to [***]provided that Tower returns the Tower Products in accordance with
Intel’s RMA procedure. If any such Tower Products is nonconforming, transportation and other charges for the shipment of replacement or repaired Tower Products to Tower will be paid by Intel (excluding customs clearance charges for ex-USA
locations, which charges will be paid by Tower). Intel will have a reasonable time to make repairs or to replace Tower Products or to credit Tower’s account. All warranty claims must be made within [***] of the date Tower learns, or with
reasonable diligence should have learned, of the nonconformance giving rise to the claim.
|
6.4 |
EXCEPT AS SET FORTH IN THIS SECTION 6, THE SERVICES, TOWER PRODUCTS, NON-PRODUCTION WAFERS, TOWER TOOLS AND ANY OTHER TECHNOLOGIES PROVIDED BY OR ON BEHALF OF INTEL (AND ALL INTELLECTUAL PROPERTY THEREIN) ARE PROVIDED “AS IS” AND INTEL
DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED OR STATUTORY, ARISING FROM COURSE OF DEALING OR USAGE OF TRADE. IN PARTICULAR, ANY AND ALL WARRANTIES OF MERCHANTABILITY, FUNCTIONALITY FOR ANY SPECIFIC PURPOSE, OR NON-INFRINGEMENT ARE
HEREBY EXPRESSLY DISCLAIMED.
|
7. |
Intellectual Property. All drawings, specifications, recipes and technical information and any other property (including any intellectual property embodied therein) furnished to Intel, shall be and
remain the sole and exclusive property of Tower or its licensors, as applicable, and is considered Tower’s Confidential Information in accordance with the CNDA (“Tower’s Property”). [***]Intel may use
Tower’s Property and any part thereof for the sole purpose of providing Services to Tower under this Agreement and Intel obtains no rights thereto except for the limited and nontransferable right above. All technical information, recipes,
specifications, drawings, and other intellectual property provided by Intel in connection with this Agreement based on Intel’s proprietary and confidential information shall at all times remain the sole and exclusive property of Intel, and
Tower obtains no rights thereto except for the limited and non-transferable license rights to rely on Intel’s intellectual property in connection with the manufacture, use, sale, export and distribution of Tower Products delivered by Intel to
Tower. Each Party may not use the other Party’s intellectual property except as set forth in this Agreement, and each Party may not attempt to reverse engineer, decompile, deconstruct or replicate the other Party’s intellectual property.
[***]
|
8. |
Representations. The Parties represent that they are fully authorized and empowered to enter into this Agreement, and that the performance of the obligations under this Agreement will not violate or
infringe upon the rights of any third party.
|
9. |
Indemnification.
|
9.1 |
[***]
|
9.2 |
[***].
|
9.3 |
[***]
|
9.4 |
Tower’s obligation under Section 9.1 is conditioned on Intel: (i) giving prompt written notice to Tower; (ii) giving Tower all needed information, assistance, and authority; and (iii) obtaining Tower’s written consent before entering into
any compromise or settlement of such claim. Tower’s obligation under Section 9.2 is conditioned on Intel giving prompt written notice to Tower and reasonably cooperating with Tower and obtaining Tower’s written consent before entering into
any compromise or settlement of such claim. Tower’s obligation under Section 9.3 is conditioned on Intel: (i) giving prompt written notice to Tower; (ii) permitting Tower to control defense and settlement; (iii) giving Tower all needed
information, assistance, and authority; and (iv) obtaining Tower’s written consent before incurring any costs or expenses or entering into any compromise or settlement of such claim.
|
9.5 |
Exclusions from Tower’s Duty to Indemnify. Notwithstanding anything in Sections 9.1 through 9.4, Tower has no obligation to indemnify or defend Intel for a claim made against modificat--ions to Tower’s Property by Intel, unless made at
Tower’s or its customer’s direction.
|
10. |
Limitation of Liability.
|
10.1 |
EXCEPT FOR: [***], IN NO EVENT WILL EITHER PARTY HAVE ANY LIABILITY TO THE OTHER PARTY, END USERS OR ANY OTHER THIRD PARTY, FOR ANY LOST ACTUAL OR ANTICIPATED PROFITS, LOSS OF THE USE OF MONEY, LOSS OF ANTICIPATED SAVINGS, LOSS OF
BUSINESS, LOSS OF OPPORTUNITY, LOSS OF GOODWILL, LOSS OF USE OF PRODUCTS, LOSS OF REPUTATION, LOSS OF, DAMAGE TO, OR CORRUPTION OF DATA, OR COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, OR FOR ANY INDIRECT, ENHANCED, SPECIAL,
EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED, ARISING OUT OF THIS AGREEMENT, UNDER ANY CAUSE OF ACTION OR THEORY OF LIABILITY, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. THESE
LIMITATIONS WILL APPLY NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN ADDITION, NEITHER PARTY WILL BE LIABLE FOR: (i) AMOUNTS ASSESSED OR AWARDED ON THE VALUE OF SERVICES OR AN ASSEMBLY OF PRODUCTS, DEVICES OR
COMPONENTS THAT INCLUDES A PRODUCT, SUBJECT TO A CLAIM UNDER SECTION 9 (INDEMNIFICATION), WHERE THAT CLAIM INCLUDES A DEMAND FOR DAMAGES ASSOCIATED WITH THE ENTIRE ASSEMBLY (E.G., DAMAGES BASED UPON THE “ENTIRE MARKET VALUE” RULE); OR (ii)
AMOUNTS ASSESSED OR AWARDED BASED ON THE VALUE OR SALES PRICE OF ANY PRODUCTS, DEVICES, COMPONENTS OR SERVICES OTHER THAN A PRODUCT INDEMNIFIED UNDER THIS AGREEMENT, WHEN AN ASSESSMENT OR AWARD INCLUDES AN ALLEGATION THAT THOSE OTHER ITEMS
WOULD HAVE BEEN SOLD TOGETHER WITH, OR AS SPARE PARTS SOLD FOR, A PRODUCT SUBJECT TO A CLAIM UNDER SECTION 9 (INDEMNIFICATION) (E.G., “CONVOYED SALES” OR “DERIVATIVE SALES”).
|
10.2 |
EXCEPT FOR: [***]), IN NO EVENT WILL EITHER PARTY’S TOTAL CUMULATIVE LIABILITY FOR CLAIMS OR CAUSES ARISING OUT OF THIS AGREEMENT OR THE TRANSACTION CONTEMPLATED THEREBY, EXCEED [***]. THE EXISTENCE OF MORE THAN ONE CLAIM AGAINST THE
PARTICULAR PRODUCTS MANUFACTURED FOR OR DELIVERED TO TOWER UNDER THIS AGREEMENT WILL NOT ENLARGE OR EXTEND THIS LIMIT.
|
10.3 |
THE PARTIES UNDERSTAND AND AGREE THAT THE FOREGOING LIABILITY LIMITATIONS ARE ESSENTIAL ELEMENTS OF THIS AGREEMENT AND THAT IN THE ABSENCE OF SUCH LIMITATIONS THE MATERIAL AND ECONOMIC TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY
DIFFERENT.
|
10.4 |
To the extent a judgment paid to a third party pursuant to Section 9 (INDEMNIFICATION) in connection with an indemnified claim includes increased damages resulting from a finding of willful infringement of any United States patent or
copyright, except to the extent such willful infringement arises from compliance with the applicable indemnitor’s written instructions relating to the claim, as applicable, the indemnitor will have no liability with respect to the amount of
such increase, provided the indemnitor will remain liable for the original amount of such damages.
|
10.5 |
The exclusions and limitations of Sections 6 (LIMITED WARRANTY), 9 (INDEMNIFICATION), and 10 (LIMITATION OF LIABILITY) will survive the termination of the Agreement and will apply notwithstanding any claim of a failure of any one or more
remedies to accomplish their purpose, and THE PARTIES EXPRESSLY WAIVE AND RELINQUISH ANY CONTRARY RIGHTS UNDER ANY AGREEMENT, AND/OR LAW, DECISION, CUSTOM OR PRACTICE.
|
11. |
Force Majeure. Excluding payment obligations, neither Party shall be liable to the other Party for any delays or failure to perform under this Agreement caused by circumstances outside such Party’s
control, including but not limited to fires, floods, government acts or regulations, and strikes (“Force Majeure Event”). In such events, the affected Party shall immediately inform the other Party of
such circumstances together with documents of proof and the performance of obligations hereunder shall be suspended during, but not longer than, the period of existence of such cause. If the Force Majeure Event prevents Intel from delivering
Tower Products, Intel shall, without obligation, discuss with Tower options for transferring the 65nm and derivative (if any) production processes for all Tower Products that may be affected to another Intel production location with prior
written consent of Tower or for implementing other measures to ensure timely supply of the Tower Products.
|
12. |
Independent Contractor Status. The Parties intend that Intel be engaged as an independent contractor. Nothing contained in this Agreement will be construed to create the relationship of employer and
employee, principal and agent, partnership or joint venture, or any other fiduciary relationship. Neither Party shall act as agent for, or on behalf of the other Party, or to represent or bind the other Party in any manner.
|
13. |
Term. This Agreement shall commence on the Effective Date, and continue thereafter until [***], unless the Parties mutually agree to extend this Agreement for an additional 5 years in writing.
|
14. |
Termination.
|
14.1 |
Termination for Material Breach. Either Party may terminate this Agreement for uncurable material breach by the other Party. For a material breach that cannot be cured, the Agreement will terminate
upon delivery of notice of the breach (or on any later date stated in the notice) by the non-breaching Party. For a material breach that is capable of being cured, the Parties will first use the process described in Section 18 (Dispute
Resolution). If the breach has not been cured, the Agreement will terminate automatically on the date of exhaustion of such process, or on the date stated in the notice of breach by the non-breaching party, whichever comes later. In cases of
breach of payment obligations by Tower that remains uncured ten (10) days after notice of delivery of the breach, Intel may, at its option, pause performance of its obligations under this Agreement until such time as the breach is cured. In
all cases, the notice of breach by the non-breaching party must identify the provisions of the Agreement that have been breached and state the facts establishing such breach.
|
14.2 |
Termination for Force Majeure Event. Intel may terminate this Agreement without penalty if a Force Majeure Event renders Intel unable to provide the Services through commercially reasonable efforts
for a continuous period of more than [***]from the date of the occurrence of the Force Majeure Event.
|
14.3 |
Effect of Termination. In the event of termination pursuant to this Section 14, neither Party shall be liable to the other Party for monetary damages arising solely as a result of such termination.
All payment obligations existing at the time of termination remain valid and in force.
|
14.3.1 |
If the Agreement is terminated by Tower pursuant to Section 14.1 (Termination for Material Breach), Intel will uninstall the Tower Tools at its expense and will make them available to Tower without unnecessary delay and this will not
derogate from any other claim Tower may have for compensation from Intel, and in addition (i) Intel will return to Tower any prepayments from Tower’s customers that Tower paid to Intel for purchase orders that remain unfulfilled as of the
date of such termination; (ii) Intel will promptly return the Tower Tools in “as-is” condition, after removing all Intel IP and Intel Confidential Information, and Tower shall be liable for all documented actual expenses incurred by Intel
in returning the Tower Tools to Tower; and (iii) Tower may sell or relocate the Tower Tools elsewhere at its sole discretion.
|
14.3.2 |
If the Agreement is terminated by Intel pursuant to Section 14.1 (Termination for Material Breach), Intel will have the option to purchase the Tower Tools at its sole discretion, on a tool-by-tool basis, for book value on Tower’s books at
the time of the breach. Tower will reimburse Intel for all documented expenses incurred by Intel in uninstalling and removing the Tower Tools for which Intel does not exercise its purchase option from the Intel facility.
|
14.3.3 |
If the Agreement is terminated pursuant to Section 14.2 (Termination for Force Majeure Event), (i) Intel will return to Tower any prepayments from Tower’s customers that Tower paid to Intel for purchase orders that remain unfulfilled as
of the date of such termination; (ii) Intel will promptly return the Tower Tools in “as-is” condition regardless of whether the Tower Tools were affected by the Force Majeure Event and Tower shall be liable for all documented actual
expenses incurred by Intel in uninstalling and returning the Tower Tools; and (iii) Tower may sell or relocate the Tower Tools elsewhere at its sole discretion.
|
14.3.4 |
Termination or expiration of this Agreement will have no effect on any signed Non-Disclosure Agreements between the Parties (including without limitation the CNDA and M-RUNDA), which remain in full force and effect as separate agreements
according to their terms.
|
14.3.5 |
The Tower Tools will be cleansed of any Intel technology, data and intellectual property as part of any uninstall of the Tower Tools prior to being provided back to Tower and Tower will have no license, express or implied, or other
intellectual property rights from Intel or its licensors to any such technology, data or intellectual property.
|
14.3.5 |
Survival. Sections 1, 5 through 11, 13 through 16, 18, and 19 will survive the termination or expiration of this Agreement.
|
15. |
Change of Control. Either Party may not assign, delegate or otherwise transfer this Agreement or any rights or obligations under this Agreement in whole or in part (whether by operation of law,
through change of control or otherwise), without the other Party’s prior written consent, which shall not be unreasonably withheld. Any prohibited assignment or transfer shall be null and void. Notwithstanding the foregoing, either Party may
assign this Agreement to its successor following an acquisition or merger of all or substantially all the assets or stock of such Party (or any transaction having a similar effect), provided the assignee or successors shall assume all
obligations under this Agreement, which will be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and permitted assignees.
|
16. |
Taxes.
|
16.1 |
Transaction Taxes. Tower will pay all applicable transaction taxes, in connection with Tower funded cap-ex and tools’ purchases and wafers, and purchase of Intel-provided services, including VAT
thereon, as imposed on a purchaser by applicable laws, including but not limited to sales and use taxes (including, without limitation any taxes imposed on Intel arising from the transfer of title to the Tower Tools acquired by Intel on
Tower’s behalf), value added taxes and other transactional charges such as duties, customs, tariffs, imposts, and government-imposed surcharges (collectively, “Transaction Taxes”). If Intel is required
by applicable law to collect from Tower and remit any Transaction Taxes to the appropriate taxing authority, Tower will pay such Transaction Taxes to Intel as reflected in an applicable invoice issued under this Agreement. If Tower is exempt
from any Transaction Taxes which Intel would otherwise be required to collect, Tower will provide proof of such exemption to Intel at least fifteen (15) business days prior to the due date for a payment. If Intel does not collect Transaction
Taxes from Tower but later remits payment of Transaction Taxes for which Tower is responsible to any taxing authority, including as a result of an audit, notice of assessment or other written communication from a taxing authority, then within
five (5) business days from receipt of a written notice from Intel, Tower will promptly reimburse Intel for such Transaction Taxes and any accrued interest and penalties if any such delay in payment is attributable to Tower.
|
16.2 |
Withholding Taxes. All payments will be made free and clear without deduction for any present and future taxes imposed by any taxing authority. If Tower is required by applicable law to deduct or
withhold income taxes (“Withholding Taxes”) therefrom, then Tower will duly withhold and will pay to Intel the remaining net amount after the deduction of
Withholding Taxes and promptly provide Intel with an official tax receipt or other evidence that Withholding Taxes have been remitted to the relevant taxing authority. Tower will provide written notice to Intel of its intent to withhold
(including details of the amounts and legal basis for Withholding Taxes) at least fifteen (15) business days prior to the due date for any payments under this Agreement and will cooperate with Intel to reduce any Withholding Taxes. If Intel
provides Tower with an official certificate or other documentation issued by the relevant taxing authority for a lower rate of, or exemption from, Withholding Taxes to be applied on the payments made by Tower to Intel, then Tower will apply
such lower rate or exemption to Withholding Taxes in accordance with such certificate or documentation.
|
17. |
Customer Engagement. Tower may provide Intel with information about its customers in order to enable Intel to manufacture Tower Products. Any such information shall be provided on a confidential
basis under the confidentiality obligations set forth herein. Absent Tower’s written pre-approval, during the term of this Agreement, Intel will not engage, directly or indirectly with Tower’s current customers regarding provision of the
Services during the term of this Agreement.
|
18. |
Dispute Resolution.
|
18.1 |
Any dispute arising directly under the express terms of this Agreement or the grounds for termination of any rights granted under this Agreement shall be resolved as follows: First, within forty five (45) calendar days from one Party’s
written request or payment demand giving rise to the dispute (including an invoice or other payment demand) to the other, senior vice presidents or higher of both Parties shall meet to attempt to resolve such dispute. If the senior vice
presidents or higher cannot resolve the dispute, either Party may then make a written demand for formal dispute resolution by tendering to the other Party notice of the dispute and its intent to invoke the terms of this Section 18. The
Parties agree to meet within forty-five (45) calendar days of such a demand with an impartial mediator selected by mutual agreement to participate in a one-day, non-binding mediation. In the event the Parties cannot agree on a mediator, they
shall each select one nominator, who shall not at that time be employed by either Party, and the two nominators shall agree on and appoint the mediator. If the Parties have not resolved the dispute or claim within thirty (30) calendar days
after the one-day, non-binding mediation, either Party may begin litigation proceedings.
|
18.2 |
This Agreement, and any dispute or claim arising out of or in connection with it or its subject matter or formation, will be governed by the laws of the State of Delaware U.S.A. and the United States notwithstanding its conflicts of laws
provision. Each Party irrevocably agrees the courts of Delaware, U.S.A. will have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with the Agreement or its subject matter or formation. The Parties waive
any objection to such choice of law, jurisdiction and venue selection. The Parties expressly reject the application of the United Nations Convention on Contracts for the International Sale of Goods.
|
19. |
Miscellaneous.
|
19.1 |
Notices. Notices must be in writing and sent to both the mailing and email address below along with a copy of this Agreement. Email delivery alone is insufficient. Paper copies must be sent by
overnight courier with tracking. Nothing in this section relates to service of process. Unless changed by notice, all notices must be addressed as follows:
|
For Intel:
|
|
Intel Corporation
2200 Mission College Boulevard
Santa Clara, CA 95054 United States of America
Attn: General Counsel
Reference ID: Sean Fernandes, IFS Legal
|
With a copy, which will not be notice, to: Intel-Legal-Notices@intel.com
And with a copy, which will not be notice, to:
Intel Corporation
Post Contract Management, M/S FM1-531900
1900 Prairie City Road
Folsom, CA 95630
Email: post.contract.mgmt@intel.com
|
For Tower:
Tower Semiconductor Ltd.,
Ramat Gavriel Industrial Park, P.O. Box 619 Migdal Haemek 23105, Israel
Attn: General Counsel
|
And with a copy, which will not be notice, to: Email: natiso@towersemi.com
|
19.2 |
Compliance with Laws. Each Party and its agents, employees, and subcontractors must comply with all applicable laws, regulations, and government orders (including those related to anti-corruption
and export control) in the performance of this Agreement.
|
19.3 |
Policies and Procedures. The Parties acknowledge and agree that in order for Intel to provide Tower with the Services there will be additional policies and procedures that will need to be provided
and adhered to and the Parties agree to work in good faith to implement and operate under such policies and procedures that reflect industry standards.
|
19.4 |
Counterparts and Signatures. This Agreement may be executed in several counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.
The Parties agree that facsimile or electronic transmission of original signatures constitute and will be accepted as original signatures.
|
19.5 |
Conflicts Among Documents. The provisions of this Agreement will prevail over different, conflicting, or additional provisions in any purchase order, acknowledgment, invoice, or other similar
document issued by either Party in connection with this Agreement. If there is any conflict between the provisions of this Agreement and any other document included or referenced in this Agreement, the descending order of precedence for
determining which terms will control is (A) the provisions of this Agreement, (B) Exhibit 1 (Foundry Product Attachment); (C) Exhibit 2 (SOW).
|
19.6 |
Severability. If a court holds a part of this Agreement unenforceable, the court will modify that part to the minimum extent necessary to make that part enforceable, or if necessary, sever that part.
The rest of this Agreement remains fully enforceable.
|
19.7 |
Entire Agreement. This Agreement, including Exhibits 1 (Foundry Product Attachment) and Exhibit 2 (SOW) and their respective addenda and schedules, if any, represents the entire agreement between
the Parties, and supersedes all prior and contemporaneous agreements, understandings, conditions, representations, warranties, and communications between the Parties relating to this Agreement’s subject matter. Amendments to this Agreement
shall only have any force and effect to the extent executed by both Parties and identified as an amendment hereto.
|
Tower Semiconductor Ltd.
|
Intel Corporation
|
By:_________________________
|
By:____________________________
|
Name:_______________________
|
Name:_________________________
|
Title:________________________
|
Title:__________________________
|
Date:________________________
|
Date:__________________________
|
Subsidiary
|
Jurisdiction
|
Ownership
|
Tower US Holdings Inc.
|
Delaware
|
100% directly
|
Tower Semiconductor NPB Holdings Inc.
|
Delaware
|
100% indirectly through Tower US Holdings Inc.
|
Tower Semiconductor Newport Beach, Inc.
|
Delaware
|
100% indirectly through Tower Semiconductor NPB Holdings Inc.
|
Newport Fab LLC
|
Delaware
|
100% indirectly through Tower Semiconductor Newport Beach Inc.
|
Tower Semiconductor San Antonio Inc.
|
Delaware
|
100% indirectly through Tower US Holdings Inc.
|
Tower Partners Semiconductor Co., Ltd.
|
Japan
|
51% directly
|
Tower Semiconductor Italy S.r.l.
|
Italy
|
100% directly
|
1. |
Purpose
|
2. |
Policy for Recovery of Erroneously Awarded Compensation
|
3. |
Application of Policy
|
4. |
Administration
|
4.1. |
This Policy shall be administered by the Compensation Committee. The Compensation Committee is authorized to interpret and construe this Policy and to make all
determinations necessary, appropriate, or advisable for the administration of this Policy.
|
4.2. |
The Company is authorized to take appropriate steps to implement this Policy and may effect recovery hereunder by: (i) requiring payment to the Company, (ii) set-off,
(iii) reducing compensation, or (iv) such other means or combination of means as the Compensation Committee determines to be appropriate.
|
4.3. |
The Company need not recover Erroneously Awarded Compensation if and to the extent that the Compensation Committee or a majority of the independent members of the
Board determines that such recovery is impracticable and not required under Rule 10D-1 and the Listing Standards, when the Compensation Committee or a majority of the independent members of the Board determines that: (i) the direct expense
paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover, (ii) recovery would violate home country law adopted prior to November 28, 2022, after obtaining
the opinion of home country counsel, or (iii) recovery would likely cause an otherwise tax-qualified broad-based retirement plan to fail the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as
amended, and regulations thereunder.
|
4.4. |
Any determinations made by the Compensation Committee under this Policy shall be final and binding on all affected individuals and need not be uniform among affected
individuals.
|
5. |
Other Recovery Rights; Company Claims
|
6. |
Reporting and Disclosure
|
7. |
Indemnification Prohibition
|
8. |
Amendment; Termination
|
9. |
Successors
|
10. |
Effective Date
|